SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
View ORCID ProfileIrina Kislaya, Pedro Casaca, View ORCID ProfileVítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, View ORCID ProfileDaniela Santos, António Maia Gonçalves, Luís Vieira, View ORCID ProfileJoão Paulo Gomes, Pedro Pinto Leite, View ORCID ProfileBaltazar Nunes, Ausenda Machado, André Peralta-Santos
doi: https://doi.org/10.1101/2022.07.25.22277996
Irina Kislaya
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
Pedro Casaca
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
Vítor Borges
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Carlos Sousa
6Unilabs, Porto, Portugal
Bibiana I. Ferreira
7Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal;Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
Eugénia Fernandes
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
Carlos Matias Dias
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
Sílvia Duarte
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
José Pedro Almeida
6Unilabs, Porto, Portugal
Inês Grenho
7Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal;Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
Luís Coelho
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Rita Ferreira
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Patrícia Pita Ferreira
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
Joana Isidro
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Miguel Pinto
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Luís Menezes
6Unilabs, Porto, Portugal
Daniel Sobral
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Alexandra Nunes
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Daniela Santos
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
António Maia Gonçalves
6Unilabs, Porto, Portugal
Luís Vieira
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
João Paulo Gomes
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
Pedro Pinto Leite
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
Baltazar Nunes
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
Ausenda Machado
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
André Peralta-Santos
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
Data Availability
Data used in the present study can be available upon reasonable request from the data owner
Posted July 25, 2022.
SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
Irina Kislaya, Pedro Casaca, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado, André Peralta-Santos
medRxiv 2022.07.25.22277996; doi: https://doi.org/10.1101/2022.07.25.22277996
SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
Irina Kislaya, Pedro Casaca, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado, André Peralta-Santos
medRxiv 2022.07.25.22277996; doi: https://doi.org/10.1101/2022.07.25.22277996
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11623)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3390)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1013)
- Primary Care Research (410)
- Public and Global Health (6021)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)